The efficacy of CAR T-cell therapy for r/r B-ALL using different approaches revealed that targeting both the CD22 and CD19 showed a positive trend of remission, as reflected by MRD-CR. The gene discussed is CD19; the disease is acute lymphoblastic leukemia.